{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T20:49:14Z","timestamp":1771361354413,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Recent clinical practice guidelines have recommended ambulatory management of febrile neutropenia in patients with low risk of complications. Although some centers have begun developing management protocols for these patients, there appears to be a certain reluctance to implement them in clinical practice. Our aim is to evaluate the strengths and weaknesses of this strategy according to available evidence and to propose new lines of research.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Systematic review using a triple aim approach (efficacy, cost-effectiveness, and quality of life), drawing from literature in MEDLINE (PubMed), Embase, and Cochrane Library databases. The review includes studies that assess ambulatory management for efficacy, cost-efficiency, and quality of life.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The search yielded 27 articles that met our inclusion criteria.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In conclusion, based on current evidence, ambulatory management of febrile neutropenia is safe, more cost-effective than inpatient care, and capable of improving quality of life in oncological patients with this complication. Ambulatory care seems to be an effective alternative to hospitalization in these patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00520-023-08065-y","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T07:02:11Z","timestamp":1698994931000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Ambulatory management of low-risk febrile neutropenia in adult oncological patients. Systematic review"],"prefix":"10.1007","volume":"31","author":[{"given":"Ester","family":"Forcano-Queralt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Lemes-Quintana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domingo","family":"Orozco-Beltr\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,13]]},"reference":[{"issue":"1","key":"8065_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2141.2006.06253.x","volume":"135","author":"J Chisholm","year":"2006","unstructured":"Chisholm J, Dommett R (2006) The evolution towards ambulatory and day-case management of febrile neutropenia. Br J Haematol 135(1):3\u201316","journal-title":"Br J Haematol"},{"issue":"9","key":"8065_CR2","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1200\/JCO.2012.45.8109","volume":"31","author":"W Kern","year":"2013","unstructured":"Kern W, Marchetti O, Drgona L, Akan H, Aoun M, Akova M, de Bock R, Paesmans M, Viscoli C, Calandra T (2013) Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin\/clavulanic acid combination therapy\u2014EORTC infectious diseases group trial XV. J Clin Oncol 31(9):1149\u20131156","journal-title":"J Clin Oncol"},{"issue":"30","key":"8065_CR3","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1200\/JCO.2011.35.0884","volume":"29","author":"J Talcott","year":"2011","unstructured":"Talcott J, Yeap B, Clark J, Siegel R, Loggers E, Lu C, Godley P (2011) Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial. J Clin Oncol 29(30):3977\u20133983","journal-title":"J Clin Oncol"},{"issue":"9","key":"8065_CR4","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s00520-007-0383-z","volume":"16","author":"C Sebban","year":"2008","unstructured":"Sebban C, Dussart S, Fuhrmann C, Ghesquieres H, Rodrigues I, Geoffrois L, Devaux Y, Lancry L, Chvetzoff G, Bachelot T, Chelghoum M, Biron P (2008) Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge. Support Care Cancer 16(9):1017\u20131023. https:\/\/doi.org\/10.1007\/s00520-007-0383-z","journal-title":"Support Care Cancer"},{"issue":"1","key":"8065_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/sj.bjc.6600993","volume":"89","author":"HE Innes","year":"2003","unstructured":"Innes HE, Smith DB, O\u2019Reilly SM, Clark PI, Kelly V, Marshall E (2003) Oral antibiotics with early hospital discharge compared with in-patient intravenous antibiotics for low-risk febrile neutropenia in patients with cancer: a prospective randomised controlled single centre study. Br J Cancer 89(1):43\u201349. https:\/\/doi.org\/10.1038\/sj.bjc.6600993","journal-title":"Br J Cancer"},{"issue":"1","key":"8065_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/(SICI)1097-0142(19990101)85:1<213::AID-CNCR29>3.0.CO;2-D","volume":"85","author":"M Hidalgo","year":"1999","unstructured":"Hidalgo M, Hornedo J, Lumbreras C, Trigo JM, Colomer R, Perea S, G\u00f3mez C, Ruiz A, Garc\u00eda-Carbonero R, Cort\u00e9s-Funes H (1999) Outpatient therapy with oral ofloxacin for patients with low risk neutropenia and fever: a prospective, randomized clinical trial. Cancer. 85(1):213\u2013219","journal-title":"Cancer."},{"issue":"3","key":"8065_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s005200050243","volume":"7","author":"V Minotti","year":"1999","unstructured":"Minotti V, Gentile G, Bucaneve G, Iori AP, Micozzi A, Cavicchi F, Barbabietola G, Landonio G, Menichetti F, Martino P, Del Favero A (1999) Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment. Support Care Cancer 7(3):134\u2013139. https:\/\/doi.org\/10.1007\/s005200050243","journal-title":"Support Care Cancer"},{"issue":"6","key":"8065_CR8","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1159\/000007240","volume":"45","author":"BL Rapoport","year":"1999","unstructured":"Rapoport BL, Sussmann O, Herrera MV, Schlaeffer F, Otero JC, Pavlovsky S, Iglesias L, Stein G, Charnas R, Heitlinger E, Handschin J (1999) Ceftriaxone plus once daily aminoglycoside with filgrastim for treatment of febrile neutropenia: early hospital discharge vs. standard in-patient care. Chemotherapy. 45(6):466\u2013476. https:\/\/doi.org\/10.1159\/000007240","journal-title":"Chemotherapy."},{"issue":"3","key":"8065_CR9","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/s0002-9343(99)80367-2","volume":"98","author":"IA Malik","year":"1995","unstructured":"Malik IA, Khan WA, Karim M, Aziz Z, Khan MA (1995) Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial. Am J Med 98(3):224\u2013231. https:\/\/doi.org\/10.1016\/s0002-9343(99)80367-2","journal-title":"Am J Med"},{"issue":"11","key":"8065_CR10","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1002\/1097-0142(19930601)71:11<3640::aid-cncr2820711128>3.0.co;2-h","volume":"71","author":"EB Rubenstein","year":"1993","unstructured":"Rubenstein EB, Rolston K, Benjamin RS, Loewy J, Escalante C, Manzullo E, Hughes P, Moreland B, Fender A, Kennedy K et al (1993) Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer. 71(11):3640\u20133646. https:\/\/doi.org\/10.1002\/1097-0142(19930601)71:11<3640::aid-cncr2820711128>3.0.co;2-h","journal-title":"Cancer."},{"issue":"14","key":"8065_CR11","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","volume":"36","author":"R Taplitz","year":"2018","unstructured":"Taplitz R, Kennedy E, Bow E, Crews J, Gleason C, Hawley D, Langston A, Nastoupil L, Rajotte M, Rolston K, Strasfeld L, Flowers C (2018) Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol 36(14):1443\u20131453","journal-title":"J Clin Oncol"},{"issue":"1","key":"8065_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s12094-018-1983-4","volume":"21","author":"A Carmona-Bayonas","year":"2019","unstructured":"Carmona-Bayonas A, Jimenez-Fonseca P, de Castro E, Mata E, Biosca M, Custodio A, Espinosa J, V\u00e1zquez E, Henao F, Ayala de la Pe\u00f1a F (2019) SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018). Clin Transl Oncol 21(1):75\u201386","journal-title":"Clin Transl Oncol"},{"issue":"16","key":"8065_CR13","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","volume":"18","author":"J Klastersky","year":"2000","unstructured":"Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038\u20133051. https:\/\/doi.org\/10.1200\/JCO.2000.18.16.3038","journal-title":"J Clin Oncol"},{"issue":"5","key":"8065_CR14","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1200\/JCO.2014.57.2347","volume":"33","author":"A Carmona-Bayonas","year":"2015","unstructured":"Carmona-Bayonas A, Jim\u00e9nez-Fonseca P, Virizuela Echaburu J, Antonio M, Font C, Biosca M et al (2015) Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the Clinical Index of Stable Febrile Neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol 33(5):465\u2013471","journal-title":"J Clin Oncol"},{"issue":"3","key":"8065_CR15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00520-006-0126-6","volume":"15","author":"T Mizuno","year":"2007","unstructured":"Mizuno T, Katsumata N, Mukai H, Shimizu C, Ando M, Watanabe T (2007) The outpatient management of low-risk febrile patients with neutropenia: risk assessment over the telephone. Support Care Cancer 15(3):287\u2013291 Epub 2006 Aug 29","journal-title":"Support Care Cancer"},{"issue":"11","key":"8065_CR16","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1002\/cncr.21908","volume":"106","author":"K Rolston","year":"2006","unstructured":"Rolston K, Manzullo E, Elting L, Frisbee-Hume S, McMahon L, Theriault R, Patel S, Benjamin R (2006) Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia: a pilot study of 40 patients based on validated risk-prediction rules. Cancer. 106(11):2489\u20132494","journal-title":"Cancer."},{"issue":"9","key":"8065_CR17","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/imj.12228","volume":"43","author":"S Lingaratnam","year":"2013","unstructured":"Lingaratnam S, Mellerick A, Worth L, Green M, Guy S, Kirsa S, Slavin M, Renwick W, Filshie R, Thursky K (2013) Feasibility of early discharge strategies for neutropenic fever: outcomes of a Victorian organisational readiness assessment and pilot. Intern Med J 43(9):979\u2013986","journal-title":"Intern Med J"},{"issue":"1","key":"8065_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00520-009-0634-2","volume":"18","author":"K Rolston","year":"2010","unstructured":"Rolston K, Frisbee-Hume S, Patel S, Manzullo E, Benjamin R (2010) Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients. Support Care Cancer 18(1):89\u201394","journal-title":"Support Care Cancer"},{"issue":"5","key":"8065_CR19","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/imj.12117","volume":"43","author":"C Hocking","year":"2013","unstructured":"Hocking C, Taylor A, Hayward A (2013) Early discharge and ambulatory care of low-risk patients with neutropenic fever in Australia. Intern Med J 43(5):591\u2013595","journal-title":"Intern Med J"},{"issue":"12","key":"8065_CR20","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1111\/imj.14136","volume":"48","author":"D Poprawski","year":"2018","unstructured":"Poprawski D, Chan J, Barnes A, Koczwara B (2018) Retrospective audit of neutropenic fever after chemotherapy: how many patients could benefit from oral antibiotic management? Intern Med J 48(12):1533\u20131535","journal-title":"Intern Med J"},{"issue":"3","key":"8065_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1177\/1078155213492450","volume":"20","author":"D Weycker","year":"2014","unstructured":"Weycker D, Barron R, Kartashov A, Legg J, Lyman G (2014) Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J Oncol Pharm Pract 20(3):190\u2013198","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"8065_CR22","doi-asserted-by":"publisher","first-page":"e259","DOI":"10.1200\/JOP.2016.017277","volume":"13","author":"L Goodman","year":"2017","unstructured":"Goodman L, Estfan B, Montero A, Kunapareddy G, Lau J, Gallagher E, Best C, Tripp B, Moeller M, Bolwell B, Stevenson J (2017) Improving the management of patients with low-risk neutropenic fever at the Cleveland Clinic Taussig Cancer Institute. J Oncol Pract 13(3):e259\u2013e265","journal-title":"J Oncol Pract"},{"issue":"9","key":"8065_CR23","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1007\/s00520-018-4194-1","volume":"26","author":"T Cooksley","year":"2018","unstructured":"Cooksley T, Campbell G, Al-Sayed T, La Mola L, Berman R (2018) A novel approach to improving ambulatory outpatient management of low risk febrile neutropenia: an Enhanced Supportive Care (ESC) clinic. Support Care Cancer 26(9):2937\u20132940","journal-title":"Support Care Cancer"},{"issue":"10","key":"8065_CR24","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"N Kuderer","year":"2006","unstructured":"Kuderer N, Dale D, Crawford J, Cosler L, Lyman G (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 106(10):2258\u20132266","journal-title":"Cancer."},{"issue":"10","key":"8065_CR25","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1185\/03007990903209563","volume":"25","author":"Mayordomo J, L\u00f3pez A, Vi\u00f1olas N, Castellanos J, Pernas S, Domingo Alonso J, Frau A, Layola M, Antonio Gasquet J, S\u00e1nchez J; ENIA Study Group","year":"2009","unstructured":"Mayordomo J, L\u00f3pez A, Vi\u00f1olas N, Castellanos J, Pernas S, Domingo Alonso J, Frau A, Layola M, Antonio Gasquet J, S\u00e1nchez J; ENIA Study Group (2009) Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin 25(10):2533\u20132542","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"8065_CR26","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/ecc.12182","volume":"24","author":"C O\u2019Brien","year":"2015","unstructured":"O\u2019Brien C, Fogarty E, Walsh C, Dempsey O, Barry M, Kennedy M, McCullagh L (2015) The cost of the inpatient management of febrile neutropenia in cancer patients\u2014a micro-costing study in the Irish healthcare setting. Eur J Cancer Care (Engl) 24(1):125\u2013132","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"21","key":"8065_CR27","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1200\/JCO.2000.18.21.3699","volume":"18","author":"L Elting","year":"2000","unstructured":"Elting L, Rubenstein E, Rolston K, Cantor S, Martin C, Kurtin D, Rodriguez S, Lam T, Kanesan K, Bodey G (2000) Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care. J Clin Oncol 18(21):3699\u20133706","journal-title":"J Clin Oncol"},{"issue":"4","key":"8065_CR28","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1200\/JCO.2007.13.8222","volume":"26","author":"L Elting","year":"2008","unstructured":"Elting L, Lu C, Escalante C, Giordano S, Trent J, Cooksley C, Avritscher E, Shih Y, Ensor J, Bekele B, Gralla R, Talcott J, Rolston K (2008) Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol 26(4):606\u2013611","journal-title":"J Clin Oncol"},{"issue":"30","key":"8065_CR29","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.1200\/JCO.2011.35.1247","volume":"29","author":"A Hendricks","year":"2011","unstructured":"Hendricks A, Loggers E, Talcott J (2011) Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. J Clin Oncol 29(30):3984\u20133989","journal-title":"J Clin Oncol"},{"issue":"3","key":"8065_CR30","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00520-017-3921-3","volume":"26","author":"B Teh","year":"2018","unstructured":"Teh B, Brown C, Joyce T, Worth L, Slavin M, Thursky K (2018) Safety and cost benefit of an ambulatory program for patients with low-risk neutropenic fever at an Australian centre. Support Care Cancer 26(3):997\u20131003","journal-title":"Support Care Cancer"},{"issue":"10","key":"8065_CR31","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1684\/bdc.2014.1958","volume":"101","author":"I Borget","year":"2014","unstructured":"Borget I, Antoun S, Chachaty E, Gachot B, Alibay A, Di Palma M, Merad M (2014) Modalities of management of cancer patients with febrile neutropenia in the oncology emergency unit of Gustave-Roussy and their related costs. Bull Cancer 101(10):925\u2013931","journal-title":"Bull Cancer"},{"issue":"11","key":"8065_CR32","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1007\/s00520-012-1397-8","volume":"20","author":"O Teuffel","year":"2012","unstructured":"Teuffel O, Cheng S, Ethier M, Diorio C, Martino J, Mayo C, Wing R, Sung L, Alibhai S (2012) Health-related with different management strategies for febrile neutropenia in adult cancer patients. Support Care Cancer 20(11):2755\u20132764","journal-title":"Support Care Cancer"},{"issue":"5","key":"8065_CR33","first-page":"1465","volume":"26","author":"S Ahn","year":"2018","unstructured":"Ahn S, Rice T, Yeung S, Cooksley T (2018) Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents. Support Care Cancer 26(5):1465\u20131470","journal-title":"Support Care Cancer"},{"issue":"8","key":"8065_CR34","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1007\/s00520-013-1787-6","volume":"21","author":"S Ahn","year":"2013","unstructured":"Ahn S, Lee Y, Lim K, Lee J (2013) Adding procalcitonin to the MASCC risk-index score could improve risk stratification of patients with febrile neutropenia. Support Care Cancer 21(8):2303\u20132308","journal-title":"Support Care Cancer"},{"key":"8065_CR35","doi-asserted-by":"publisher","first-page":"492","DOI":"10.7326\/0003-4819-121-7-199410010-00004","volume":"121","author":"D Mather","year":"1994","unstructured":"Mather D, Lieschke G, Green M (1994) Filgastrim in patients with chemotherapy-induced febrile neutropenia. Ann Intern Med 121:492\u2013501","journal-title":"Ann Intern Med"},{"issue":"25","key":"8065_CR36","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1200\/JCO.2005.03.9909","volume":"24","author":"J Klastersky","year":"2006","unstructured":"Klastersky J, Paesmans M, Georgala A, Muanza F, Plehiers B, Dubreucq L et al (2006) Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24(25):4129\u20134134. Disponible en:. https:\/\/doi.org\/10.1200\/JCO.2005.03.9909","journal-title":"J Clin Oncol"},{"issue":"9","key":"8065_CR37","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/bjc.2011.101","volume":"104","author":"O Teuffel","year":"2011","unstructured":"Teuffel O, Ethier M, Alibhai S, Beyene J, Sung L (2011) Cost effectiveness of outpatient treatment for febrile neutropaenia in adult cancer patients. Br J Cancer 104(9):1377\u20131383","journal-title":"Br J Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08065-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-08065-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08065-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T09:08:16Z","timestamp":1705136896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-08065-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["8065"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-08065-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"25 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Missing Open Access funding information has been added in the Funding Note.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval was obtained from the ethics committee of University Miguel Hernandez de Elche. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Personal information is unidentifiable in this present study; and patient consent cannot be obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"665"}}